In short
Saffron is a spice with a genuinely strong evidence base for mood. Randomised trials, including recent ones in healthy adults with low mood, find it improves mood and wellbeing, and meta-analyses in clinical depression report effects comparable to standard treatments. LAYER ZERO uses a 30 mg standardised extract in the daytime layer, at the dose the trials use, for mood support across a demanding day. It is a food supplement, not a treatment for depression, and we hold that line clearly.
Most mood ingredients have thin evidence dressed up in strong language. Saffron is the rare case of the opposite: real data, which makes it more important, not less, to be careful about what we claim.
01What saffron is
Saffron is the dried stigma of the Crocus sativus flower, one of the most valuable spices by weight. Its studied activity is attributed mainly to two compounds, crocin and safranal, which is why a serious supplement is standardised to both. LAYER ZERO uses an extract standardised to 3% crocin and 2% safranal, so the active compounds are defined rather than left to the variability of raw spice.
Definition · Crocin and safranal
The two compounds most associated with saffron's effects on mood. Crocin gives saffron its colour and safranal its aroma; standardising an extract to both is how a supplement delivers a consistent, studied amount.
02What the evidence shows
Saffron is one of the best-studied botanicals for mood. A 2025 randomised, placebo-controlled trial in healthy adults experiencing low mood found improvements in mood and general wellbeing over daily use.1 That healthy-population result matters, because it speaks to exactly the everyday low mood a daily supplement is for, rather than a clinical condition.
Behind it sits a larger clinical literature. A 2024 meta-analysis of randomised trials found saffron produced improvements in depression and anxiety comparable to standard antidepressant treatment in the studies examined,2 and an umbrella review pooling multiple meta-analyses concluded that saffron meaningfully relieves depressive symptoms as studied.3 The direction and consistency of this evidence is unusually strong for a botanical.
03Why the daytime layer, at 30 mg
Saffron sits in LAYER TWO, the daytime layer built around resilience: holding steady mood and composure through the pressures of the day. Its placement there is deliberate, and so is the amount. The 30 mg dose is not a fraction of a research dose the way some ingredients are; it matches the dose used in the standardised-extract trials, which typically run around 28 to 30 mg a day. What the studies tested is close to what the layer delivers.
04Mood support, not treatment
Because saffron's evidence extends into clinical depression, the line has to be explicit. LAYER ZERO uses saffron for everyday mood support in the context of a demanding day. It is a food supplement, not a medicine, and nothing here is a claim to treat, cure, or manage depression or any other condition. If you are experiencing persistent low mood or depression, that is a matter for a doctor, and a supplement is not a substitute for care.
05What is still uncertain
Where the evidence has caveats
Many saffron trials are relatively short, some are small, and a number were conducted or funded by parties with a commercial interest, which raises the possibility of publication bias in a positive direction. The strong clinical results are in populations with diagnosed depression, which do not transfer directly to a healthy person taking a daily supplement. There is no specific European authorised health claim for saffron. We grade it as one of the stronger botanicals here while keeping its claim to everyday mood support.
06The research horizon
Saffron's evidence base is scaling up rather than thinning out. The largest trial of a standardised saffron extract to date, 202 adults with low mood over 12 weeks, published in the Journal of Nutrition in 2025, found significantly greater improvement than placebo, with 72 percent of the saffron group responding against 54 percent, and effects emerging from week five.4 A 2024 meta-analysis in Nutrition Reviews pooled trials comparing saffron against prescription antidepressants in mild to moderate depression and found comparable effects: clinical territory, studied under clinical supervision, and cited here for what it says about the plant, not as a promise of this product.5 The extract in LAYER TWO has its own trial record: Saffr'Activ itself has been studied clinically, which is the standard we hold branded ingredients to.6 New publications keep arriving, including a 2025 trial from a French national research group in a major clinical nutrition journal and a 2026 trial in women aged 50 to 70. For a spice crocus, this is a remarkably serious literature, and it is still growing.
07How LAYER ZERO uses this
The daytime layer is about resilience under pressure, and mood is part of resilience. Saffron is the component aimed at that, chosen because it is one of the few botanicals whose mood evidence is genuinely solid, and dosed to match the research. It is a good example of the standard the whole system tries to hold: use the things that are actually supported, at the amounts that were actually studied, and describe them honestly.
In the system
LAYER TWO is the daytime layer, built for resilience across the demands of the day. Saffron is its mood-support component, at the studied dose. To see where your own hardest hours fall, the protocol builder maps them in about three minutes. Build your protocol →
Sources
Next in this thread
Rhodiola roseaAnother botanical aimed at resilience, and a useful contrast in how strong the evidence is.→How we handle evidence. Every claim on this page is graded and linked to a primary source, and we say where the science is not yet settled. This page is educational and is not medical advice or a health claim about any product.